Artiva Biotherapeutics, Inc. (ARTV) vs Viemed Healthcare, Inc. (VMD)
A side-by-side comparison of Artiva Biotherapeutics, Inc. and Viemed Healthcare, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARTV
Artiva Biotherapeutics, Inc.
$7.27HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VMD
Viemed Healthcare, Inc.
$9.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ARTV vs VMD
growth of $100 · dividends reinvested · last 2yARTV -40.6% (-22.9%/yr)VMD +28.5% (+13.4%/yr)VMD compounded faster over this window
ARTV VMD
ARTV vs VMD: by the numbers
- •ARTV is the larger company ($355M vs $355M market cap).
- •VMD is profitable (4.81% net margin) while ARTV runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ARTV | VMD |
|---|---|---|
| P/E ratio | N/A | 25.65 |
| Forward P/E | N/A | 22.57 |
| P/S ratio | N/A | 1.18 |
| P/B ratio | 1.02 | 2.47 |
| EV / EBITDA | N/A | 6.50 |
| FCF yield | N/A | 8.23% |
Profitability
| Metric | ARTV | VMD |
|---|---|---|
| Gross margin | 0.00% | 57.21% |
| Operating margin | 0.00% | 8.14% |
| Net margin | 0.00% | 4.81% |
| ROE | -26.14% | 10.07% |
| ROIC | -27.16% | 11.00% |
Growth (annualized)
| Metric | ARTV | VMD |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 20.15% |
| EPS CAGR (5Y) | N/A | -15.07% |
| FCF CAGR (5Y) | N/A | -11.57% |
| Total return CAGR (5Y) | N/A | 10.93% |
Frequently asked
- Is ARTV or VMD more profitable?
- VMD runs the higher net margin — ARTV at 0.00% versus VMD at 4.81%.
Go deeper
Dig into the metrics
Viemed Healthcare P/E ratioArtiva Biotherapeutics ROEViemed Healthcare ROEArtiva Biotherapeutics operating marginViemed Healthcare operating marginArtiva Biotherapeutics revenue growthViemed Healthcare revenue growthArtiva Biotherapeutics free cash flowViemed Healthcare free cash flow
Artiva Biotherapeutics & Viemed Healthcare appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.